Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Abstract

High-throughput 'omics' technologies that generate molecular profiles for biospecimens have been extensively used in preclinical studies to reveal molecular subtypes and elucidate the biological mechanisms of disease, and in retrospective studies on clinical specimens to develop mathematical models to predict clinical endpoints. Nevertheless, the… (More)
DOI: 10.1186/1741-7015-11-220

Topics

2 Figures and Tables

Cite this paper

@inproceedings{McShane2013CriteriaFT, title={Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration}, author={Lisa M. McShane and Margaret M. Cavenagh and Tracy G. Lively and David A. Eberhard and William L. Bigbee and P. Mickey Williams and Jill P. Mesirov and Mei-Yin C. Polley and Kelly Y. Kim and James V Tricoli and Jeremy M G Taylor and Deborah J. Shuman and Richard M. Simon and James H. Doroshow and Barbara A. Conley}, booktitle={BMC medicine}, year={2013} }